Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04
NCT ID: NCT00949338
Last Updated: 2014-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
183 participants
INTERVENTIONAL
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized clinical trial is comparing two sets of bladder-filling instructions in treating patients with prostate cancer undergoing radiation therapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To compare the consistency in bladder volumes in patients with prostate cancer undergoing conformal radiotherapy, when randomized to one of two sets of bladder-filling instructions.
Secondary
* To compare the incidence of acute and late genitourinary and gastrointestinal toxicity in patients treated with these methods.
* To determine patient satisfaction with the bladder-filling instructions.
* To determine satisfaction of bladder-filling protocols amongst radiation therapists and doctors.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
* Arm II: Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
In both arms, patients follow their bladder filling instructions and then undergo conformal radiation therapy daily for about 8 weeks.
Patients' perception of symptoms, quality of life, and urinary symptoms are assessed periodically by the International Prostate Symptom Score (I-PSS). Patients' satisfaction with the bladder-filling instructions (i.e., ability to comply with the bladder-filling protocol, the number of incidents of wetting accidents, number of incidents of having to repeat the water drinking on the same day due to machine breakdown or the patient's inability to retain the full bladder for the required amount of time, and the level of frustration) is assessed periodically by the Visual Analogue Scale (VAS).
Staff satisfaction with bladder-filling interventions (i.e., patient compliance with the protocols, acceptance of bladder dose-volume histograms \[DVHs\], need for re-scan with a fuller bladder, amount of disruption to the therapist's work schedule, number of incidents of wetting accidents, number of incidents of having to repeat the water drinking on the same day due to machine breakdown or the patient's inability to retain the full bladder for the required amount of time, and the level of satisfaction or frustration) is assessed periodically.
After completion of study treatment, patients are followed up periodically for 4 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
pre-procedural preparation
Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
Arm II
Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
pre-procedural preparation
Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pre-procedural preparation
Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of prostate cancer
* Undergoing a radical course of radiotherapy
* Planned treatment in the supine position
PATIENT CHARACTERISTICS:
* Karnofsky performance status 60-100%
* No history of urinary incontinence or urinary catheterization
* No evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial or if it is felt by the research/medical team that the patient may not be able to comply with the protocol
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No previous surgery for urinary conditions, except transurethral resection of the prostate (TURP)
* Prior transrectal ultrasound (TRUS) allowed
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Trials Ireland
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Thirion, MD
Role: PRINCIPAL_INVESTIGATOR
Saint Luke's Hospital
John Gerard Armstrong, MD, MB, MRCPI
Role: PRINCIPAL_INVESTIGATOR
Saint Luke's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Luke's Radiation Oncology Network
Dublin, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICORG-05-04
Identifier Type: -
Identifier Source: secondary_id
EU-20923
Identifier Type: -
Identifier Source: secondary_id
05-04 ICORG
Identifier Type: -
Identifier Source: org_study_id